For years, the Drug Enforcement Administration has classified marijuana as a Schedule I substance, alongside many harmful drugs, including heroin, ecstasy, and LSD. Recently, U.S. President Donald Trump has pushed for the rescheduling of marijuana, and last week, his administration eased the rules for licensed… Read More »Marijuana Rescheduling Has Arrived. Don’t Make This Mistake

This AI rally has quickly turned into a data center rally, where you won’t find anything for a sensible price. But that’s only if you ignore this stock. Before we reveal it, it’s a good idea to look at what other “pick and shovel” options… Read More »I’ll Buy This 1 Pick-And-Shovel AI Stock With My Eyes Closed – Here’s Why

SpaceX is preparing for what could be the most consequential stock market event in a generation. In early April 2026, the company confidentially filed paperwork with the SEC for an IPO, with executives reportedly gearing up for roadshows in early June and a summer 2026… Read More »SpaceX IPO: What Everyday Investors Need To Know Before The Biggest Stock Offering In History

Drones that cost $10,000 to $100,000. Missiles that cost millions to shoot them down. Lasers that cost $10 per shot. Memorize those numbers. The conflicts over the next decade and beyond are going to be based on them. To be clear, I don’t want any… Read More »The 3 Numbers You Need To Know About The Economics Of War

The Centers for Medicare & Medicaid Services (CMS) finalized the 2027 Medicare Advantage payment rate at a +2.48% net average increase, well above the +0.09% proposed in January and above the roughly 1% street expectation. The decision injects over $13 billion into private insurers serving… Read More »5 Stocks That Should Benefit From The 2026 Medicare Advantage Rate Decision

While defense names grabbed the headlines in the immediate aftermath of the start of the Iran war, an unlikely winner emerged from the ensuing shock to the market, with gains of 75% year to date. The broader market has wrestled with supply shocks and inflation… Read More »The Non-Defense Winner Investors Missed In The Iran War Supply Shock

Nike (NYSE:NKE) shares were down 11% in early Wednesday trading, reacting to a quarterly earnings report that beat estimates on the surface but delivered a forward outlook that rattled investors. The selloff pushes NKE stock toward levels not seen in years. The headline numbers looked… Read More »Nike Plummets On Disappointing Forecast: Generational Buy Or Value Trap?

Starbucks’ (NASDAQ: SBUX) stock is down 10% in the last year, while the S&P 500 is 12% higher. Over five years, the stock is down 20% while the S&P is up 62%. Recently, The Wall Street Journal wrote that “Starbucks Has Its Shine Back, CEO… Read More »Starbucks Is Still A Dog

Value stocks are making a comeback, and this comeback could last for a long time as investors rotate away from growth stocks. The following three stocks are currently among the most undervalued value stocks, and a comeback is yet to lift them substantially. That’s exactly… Read More »3 Value Stocks Set To Surge, With Up To 100% Upside By 2028